Skip to content

Author

D. Cosentini

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Prognostic value of hormone receptor expression in patients with HR+/HER2− advanced BC treated with first-line ET+CDK4/6i: results from the multicentre observational, real-world PALMARES-2 study

Effectiveness of first-line ET plus CDK4/6i in patients with HR+/HER2− aBC worsens progressively with decreasing ERα expression, and PgR expression adds further prognostic discrimination, with low ERα and PgR expression identifying a subgroup of patients with particularly poor outcomes.

F. Ligorio, L. Provenzano, R. Caputo et al. · 0 citations
Open access Sep 2026

Use of Metronomic Chemotherapy in Hormone Receptor‐Positive/HER2‐Negative Metastatic Breast Cancer: A Retrospective Multicenter Study

ABSTRACT Purpose The optimal chemotherapy strategy after progression on cyclin‐dependent kinase 4/6 inhibitors (CDK4/6i) in hormone receptor‐positive/human epidermal growth factor receptor 2‐negative (HR+/HER2−) metastatic breast cancer remains a matter of controversy. This study evaluated the efficacy of metronomic ch...

Lara Laini, D. Cosentini, M. Laganà et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.